Receptor Protein-Tyrosine Kinases

"Receptor Protein-Tyrosine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity.

Descriptor ID	D020794
MeSH Number(s)	D08.811.913.696.620.682.725.400 D12.776.543.750.630
Concept/Terms	Receptor Protein-Tyrosine Kinases Receptor Protein-Tyrosine Kinases Kinases, Receptor Protein-Tyrosine Protein-Tyrosine Kinases, Receptor Receptor Protein Tyrosine Kinases Receptors, Protein-Tyrosine Kinase Protein-Tyrosine Kinase Receptors Receptors, Protein Tyrosine Kinase PTK Receptors Receptors, PTK Tyrosine Kinase Receptors Protein-Tyrosine Kinase Receptor Receptor, Protein-Tyrosine Kinase Receptor Protein-Tyrosine Kinase Kinase, Receptor Protein-Tyrosine Protein-Tyrosine Kinase, Receptor Receptor Protein Tyrosine Kinase Tyrosine Kinase Linked Receptors

Below are MeSH descriptors whose meaning is more general than "Receptor Protein-Tyrosine Kinases".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]

Below are MeSH descriptors whose meaning is related to "Receptor Protein-Tyrosine Kinases".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptor Protein-Tyrosine Kinases" by people in this website by year, and whether "Receptor Protein-Tyrosine Kinases" was a major or minor topic of these publications.

Bar chart showing 32 publications over 16 distinct years, with a maximum of 4 publications in 2010 and 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	0	1	1
1998	0	1	1
2002	1	1	2
2003	1	0	1
2004	0	1	1
2005	1	2	3
2007	1	0	1
2008	1	0	1
2009	1	0	1
2010	4	0	4
2013	3	1	4
2014	2	0	2
2015	2	1	3
2016	3	0	3
2017	3	0	3
2020	1	0	1

Below are the most recent publications written about "Receptor Protein-Tyrosine Kinases" by people in Profiles.

Melson AT, McClelland CM, Lee MS. Ocular myasthenia gravis: updates on an elusive target. Curr Opin Neurol. 2020 02; 33(1):55-61.

View in: PubMed
Salat H, Din NU, Moatter T, Kayani N, Ahmed A. Anaplastic lymphoma kinase protein positive diffuse large B cell lymphoma; A developing world experience. Pathol Res Pract. 2017 Jun; 213(6):649-653.

View in: PubMed
Zaware N, Kisliuk R, Bastian A, Ihnat MA, Gangjee A. Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. Bioorg Med Chem Lett. 2017 04 01; 27(7):1602-1607.

View in: PubMed
Thorne-Nuzzo T, Williams C, Catallini A, Clements J, Singh S, Amberson J, Dickinson K, Gatalica Z, Ho SN, Loftin I, McElhinny A, Towne P. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib. J Thorac Oncol. 2017 05; 12(5):804-813.

View in: PubMed
Pavana RK, Choudhary S, Bastian A, Ihnat MA, Bai R, Hamel E, Gangjee A. Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents. Bioorg Med Chem. 2017 01 15; 25(2):545-556.

View in: PubMed
Orme JJ, Du Y, Vanarsa K, Mayeux J, Li L, Mutwally A, Arriens C, Min S, Hutcheson J, Davis LS, Chong BF, Satterthwaite AB, Wu T, Mohan C. Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE. Clin Immunol. 2016 08; 169:58-68.

View in: PubMed
Sharma J, Pareek V, Liu H, Cheng H. Emerging treatment for ALK-positive lung cancer. Expert Opin Emerg Drugs. 2016 Jun; 21(2):147-55.

View in: PubMed
Bieniasz M, Radhakrishnan P, Faham N, De La O JP, Welm AL. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. Clin Cancer Res. 2015 Dec 15; 21(24):5588-600.

View in: PubMed
Dang TT, Esparza MA, Maine EA, Westcott JM, Pearson GW. ?Np63a Promotes Breast Cancer Cell Motility through the Selective Activation of Components of the Epithelial-to-Mesenchymal Transition Program. Cancer Res. 2015 Sep 15; 75(18):3925-35.

View in: PubMed
Sinha S, Boysen J, Nelson M, Secreto C, Warner SL, Bearss DJ, Lesnick C, Shanafelt TD, Kay NE, Ghosh AK. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. Clin Cancer Res. 2015 May 01; 21(9):2115-26.

View in: PubMed

People

Explore

Similar Concepts

Top Journals